Zolasta or zoledronate (marketed by Novartis under the trade names Zometa Zomera Aclasta and Reclast) is a bisphosphonate Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases An annual dose of Zolasta may also prevent recurring fractures in patients with a previous hip fracture Reclast is a single 5 mg infusion for the treatment of Paget's disease of bone.